Navigation Links
Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH)
Date:12/4/2009

NEW YORK, Dec. 4 /PRNewswire/ -- Stemline Therapeutics, Inc. today announced that data from pre-clinical studies of its IL-3R targeting agents, SL-401 and SL-501, in both in vitro and animal models of human chronic myeloid leukemia (CML) have been selected for poster presentation at the upcoming 51st Annual Meeting of the American Society of Hematology (ASH), to be held in New Orleans from December 5-8, 2009. The poster will be presented by Stemline's collaborators at The University of Texas M.D. Anderson Cancer Center.

The data demonstrate in vitro and in vivo activity of both SL-401 and SL-501 against CML and CML cancer stem cells as single agents, and in combination with tyrosine kinase inhibitors (TKIs). Results also include activity of these IL-3R targeting agents against CML cells with mutations that render them resistant to TKIs.

Details on the abstract selected for presentation are as follows:


Abstract #:          2172

TITLE:               Targeting IL-3 Receptor in Chronic Myeloid Leukemia

Lead Author          Olga Frolova, MD, PhD

Session Name         Chronic Myeloid Leukemia -Biology and Pathophysiology
                     excluding Therapy Poster I

Date                 Sunday, December 6, 2009

Presentation Time:   6:00PM - 8:00PM

Location:            Hall E (Ernest N. Morial Convention Center)

Poster Board no.:    II-149

A copy of the above referenced abstract can be viewed online through the ASH website (www.hematology.org).

About Stemline Therapeutics, Inc.

Stemline Therapeutics, Inc. is a clinical stage biotechnology company developing novel oncology compounds directed to cancer stem cell targets. Stemline's lead compound, SL-401, targets the interleukin-3 receptor which is expressed on multiple hematological cancers including leukemia blasts and leukemia cancer stem cells.
'/>"/>

SOURCE Stemline Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Stemline Therapeutics Raises $12.5 Million
2. Stemline Therapeutics CEO to Present at IBCs New Frontiers in Cancer Drug Development Conference
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
5. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
6. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
7. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
8. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
9. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
10. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
11. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... (PRWEB) August 01, 2014 Chantel Lee ’15 ... research for 10 40-hour weeks with Dr. Juan Rodriguez, Professor ... diabetic retinopathy, a common diabetic eye disease caused by changes ... "What Chantel and Eli accomplished is quite remarkable,” said Rodriguez. ... a concept when they started, and together carried it to ...
(Date:8/1/2014)... Frederick, MD (PRWEB) August 01, 2014 ... and RFID Solutions provider, today officially announces the ... the prestigious Boji Science Park, Baoshan District in ... RURO Shanghai is under the management of Mr. ... International. , In the past three years, RURO’s ...
(Date:8/1/2014)... 1, 2014 The  PROPEL Center  of the  ... success rate of early-stage life sciences companies in ... awarded 15 grants to help Illinois ... Conference   in Chicago .   ... North America , bringing more than ...
(Date:8/1/2014)... BCC Research ( http://www.bccresearch.com ) reveals ... AND GLOBAL MARKETS , that the global market RNA ... to nearly $38.8 billion by 2018, with a five-year ... delivery category, the fastest moving segment of the market, ... field of RNAi therapeutics has shown tremendous growth and ...
Breaking Biology Technology:Two Centenary College Students Tackle Diabetic Retinopathy Research 2RURO Opens Office in Shanghai, China 2iBIO Institute's PROPEL Center Awards Grants for AdvaMed 2014 to Early-Stage Life Sciences Companies 2iBIO Institute's PROPEL Center Awards Grants for AdvaMed 2014 to Early-Stage Life Sciences Companies 3iBIO Institute's PROPEL Center Awards Grants for AdvaMed 2014 to Early-Stage Life Sciences Companies 4Global Market for RNAi Drug Delivery Technologies to Reach $38.8 Billion in 2018; Aptamer Delivery Segment Surging at 58.2% CAGR 2Global Market for RNAi Drug Delivery Technologies to Reach $38.8 Billion in 2018; Aptamer Delivery Segment Surging at 58.2% CAGR 3
... 28 Pharmacopeia,(Nasdaq: PCOP ), an innovator ... therapeutics, today announced advancements for two members,of its ... and,Regulatory Affairs, has been promoted to Senior Vice ... S. David Kimball, Ph.D., Senior,Vice President, Chemistry and ...
... DIEGO, Feb. 28 Anadys Pharmaceuticals,Inc. (Nasdaq: ANDS ... a,Phase I study of ANA773, the company,s oral TLR7 ... trial is a safety,and tolerability study designed to identify ... to select the dose and,schedule for Phase II trials., ...
... report in the February 28, 2008, New England Journal ... Newborn Screening Program (NENSP) of the University of Massachusetts ... genetic disease, providing what may be the first demonstration ... , The state of Massachusetts has offered universal ...
Cached Biology Technology:Pharmacopeia Announces Management Team Changes 2Pharmacopeia Announces Management Team Changes 3Pharmacopeia Announces Management Team Changes 4Pharmacopeia Announces Management Team Changes 5Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients 2Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients 3Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients 4Data show a decline in cystic fibrosis since introduction of prenatal carrier screening 2
(Date:7/31/2014)... beneath many of the roughly 156,000 gas stations ... corrosion in parts of underground gas storage tankscorrosion ... of groundwater, a source of drinking water. In ... reported many rapidly corroding gas storage tank components ... associated with use of gasoline-ethanol blends and the ...
(Date:7/31/2014)... models against the highly infectious and virulent bacterium, ... kills approximately 30,000 Americans annually. The research is published ... , In the study, the vaccine protected the ... by C. difficile , as well as from ... the human disease, after only two immunizations. , ...
(Date:7/31/2014)... has been made to help better identify and treat those ... narrowing and enlarging of medium sized arteries in the body, ... organs causing damage. In a new report appearing in August ... scientists provide evidence that that FMD may not be limited ... a connection to abnormalities of bones and joints, as well ...
Breaking Biology News(10 mins):NIST corrosion lab tests suggest need for underground gas tank retrofits 2C. difficile vaccine proves safe, 100 percent effective in animal models 2Scientists discover biochemical mechanisms contributing to fibromuscular dysplasia 2
... and 17 September, in the context of France,s presidency ... GMES 2008, at the Grand Palais. The GMES ... set up to provide services relating to the environment, ... services draw on data - mainly Earth observation data ...
... for oceanic vessels has been impeded by worldwide concerns ... gas emissions that impact the Earth,s climate. A ... examines "Emission Tradeoffs among Alternative Marine Fuels: Total Fuel ... Marine Diesel Oil," in a recent issue of ...
... The 2009 Force Protection Equipment,Demonstration (FPED VII) ... VA, and Marine Corps Base, Quantico, VA, next ... Global War on Terror., The demonstration is ... of commercial off-the-shelf equipment solutions to current,and evolving ...
Cached Biology News:Major European program for the environment under the spotlight in Lille, France 2Fuel emissions from marine vessels remain a global concern 22009 Force Protection Equipment Demonstration Set for Next May 19-21 2
... Acridinium NHS ester can ... and nucleic acids. The covalently ... produce chemiluminescence in the presence ... ester-labeled proteins can be used ...
... 2-color real-time PCR detection system holds 48 x ... array of 48 LEDs independently excites fluorescence (470-500 ... filtered photodiodes detects emitted light (523-543 nm and ... MJ Mini cycler, whose Peltier heat pumps provide ...
... flow cytometry accessible to anyone in the lab. ... addition to Guavas on-demand microcapillary flow cytometry systems ... use, surprisingly affordable, very compact, and nicely equipped ... Guava EasyCyte Mini has all of the functionality ...
... hold up to 6 strain chambers with precise ... use design ensures that cells grow over long ... compression. This unit allows you to control the ... 64 unique strain settings. The instrument fits in ...
Biology Products: